Delta-8 THC arrived on the market around December 2020. Its unique effects gained attention from consumers and retailers alike. But it’s not the only minor cannabinoid out there.
From CBN and CBG to delta-8, delta-10, and THCv, innovations with minor cannabinoids are just getting started. Market research firm Brightfield Group data shows cannabis consumers are expressing interest in newer cannabinoids, like THCv or CBG.
According to Brightfield Group data, 21% of cannabis consumers said they were either “likely” or “very likely” to purchase delta-8, followed by delta-10 at 18%.
“More knowledge and accessibility of minor cannabinoids will yield more tailored cannabis experiences and innovative marketing opportunities,’ Brightfield Group reports. “For example, THCv is being positioned for weight loss, whereas CBN has been positioned for sleep.”
Brands in legal cannabis markets and the U.S. CBD industry are experimenting with combinations of cannabinoids, some with THC and some without.
“Although there’s more research to be done on minor cannabinoids’ best uses and effects,” said Brightfield Group, “there seems to be a growing group of consumers looking to expand their cannabis experiences beyond delta-9.”
